CIPLA CINACALCET cinacalcet (as hydrochloride) 90 mg tablet bottle

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

cinacalcet hydrochloride, Quantity: 99.191 mg (Equivalent: cinacalcet, Qty 90 mg)

Disponible desde:

Cipla Australia Pty Ltd

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake

Vía de administración:

Oral

Unidades en paquete:

28's

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Cipla Cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (HPT) in patients with end stage renal disease, receiving dialysis (see section 5.1 Pharmacodynamic properties, Clinical trials). Cipla Cinacalcet should be used as adjunctive therapy.,Cipla Cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,Cipla Cinacalcet may be used to treat the biochemical manifestations of primary HPT in patients for whom parathyroidectomy is not a treatment option.

Resumen del producto:

Visual Identification: Light green coloured, oval shaped, biconvex film-coated tablets, debossed with "CL" on one side and "412" on other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Estado de Autorización:

Registered

Fecha de autorización:

2023-02-07